{"id":32964,"date":"2025-05-07T14:07:02","date_gmt":"2025-05-07T06:07:02","guid":{"rendered":"https:\/\/flcube.com\/?p=32964"},"modified":"2025-05-07T14:07:03","modified_gmt":"2025-05-07T06:07:03","slug":"astrazenecas-calquence-gains-eu-approval-for-mantle-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32964","title":{"rendered":"AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma"},"content":{"rendered":"\n

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN<\/a>) announced receiving another indication approval in the European Union (EU) for its Calquence (acalabrutinib), a second-generation selective Bruton tyrosine kinase (BTK) inhibitor. The drug can now be used in combination with bendamustine and rituximab to treat adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval follows the recent nod for Calquence monotherapy for the treatment of adult patients with relapsed or refractory MCL in the region.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The approval is based on results from the Phase III ECHO study, which showed that the Calquence combination reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy. The median progression-free survival (PFS) was 66.4 months for the Calquence group versus 49.6 months in the chemoimmunotherapy group.<\/p>\n\n\n\n

Acquisition and Global Registration<\/strong>
AstraZeneca obtained Calquence through the acquisition of a 55% stake in Acerta Pharma for USD 4 billion in 2016. The drug is registered in the US, Japan, China, and other markets, with indications covering B-cell associated hematological tumors such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European…<\/p>\n","protected":false},"author":1,"featured_media":32966,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,16,871,15,33],"class_list":["post-32964","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astrazeneca","tag-cancer","tag-nasdaq-azn","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"\nAstraZeneca's Calquence Gains EU Approval for Mantle Cell Lymphoma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European Union (EU) for its Calquence (acalabrutinib), a second-generation selective Bruton tyrosine kinase (BTK) inhibitor. The drug can now be used in combination with bendamustine and rituximab to treat adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval follows the recent nod for Calquence monotherapy for the treatment of adult patients with relapsed or refractory MCL in the region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32964\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca's Calquence Gains EU Approval for Mantle Cell Lymphoma\" \/>\n<meta property=\"og:description\" content=\"UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European Union (EU) for its Calquence (acalabrutinib), a second-generation selective Bruton tyrosine kinase (BTK) inhibitor. The drug can now be used in combination with bendamustine and rituximab to treat adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval follows the recent nod for Calquence monotherapy for the treatment of adult patients with relapsed or refractory MCL in the region.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32964\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-07T06:07:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-07T06:07:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0709.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma\",\"datePublished\":\"2025-05-07T06:07:02+00:00\",\"dateModified\":\"2025-05-07T06:07:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964\"},\"wordCount\":199,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0709.webp\",\"keywords\":[\"AstraZeneca\",\"Cancer\",\"NASDAQ: AZN\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32964#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32964\",\"name\":\"AstraZeneca's Calquence Gains EU Approval for Mantle Cell Lymphoma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0709.webp\",\"datePublished\":\"2025-05-07T06:07:02+00:00\",\"dateModified\":\"2025-05-07T06:07:03+00:00\",\"description\":\"UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European Union (EU) for its Calquence (acalabrutinib), a second-generation selective Bruton tyrosine kinase (BTK) inhibitor. The drug can now be used in combination with bendamustine and rituximab to treat adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval follows the recent nod for Calquence monotherapy for the treatment of adult patients with relapsed or refractory MCL in the region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32964\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0709.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0709.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca's Calquence Gains EU Approval for Mantle Cell Lymphoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32964#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca's Calquence Gains EU Approval for Mantle Cell Lymphoma - Insight, China's Pharmaceutical Industry","description":"UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European Union (EU) for its Calquence (acalabrutinib), a second-generation selective Bruton tyrosine kinase (BTK) inhibitor. The drug can now be used in combination with bendamustine and rituximab to treat adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval follows the recent nod for Calquence monotherapy for the treatment of adult patients with relapsed or refractory MCL in the region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32964","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's Calquence Gains EU Approval for Mantle Cell Lymphoma","og_description":"UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European Union (EU) for its Calquence (acalabrutinib), a second-generation selective Bruton tyrosine kinase (BTK) inhibitor. The drug can now be used in combination with bendamustine and rituximab to treat adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval follows the recent nod for Calquence monotherapy for the treatment of adult patients with relapsed or refractory MCL in the region.","og_url":"https:\/\/flcube.com\/?p=32964","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-07T06:07:02+00:00","article_modified_time":"2025-05-07T06:07:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0709.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32964#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32964"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma","datePublished":"2025-05-07T06:07:02+00:00","dateModified":"2025-05-07T06:07:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32964"},"wordCount":199,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32964#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0709.webp","keywords":["AstraZeneca","Cancer","NASDAQ: AZN","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32964#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32964","url":"https:\/\/flcube.com\/?p=32964","name":"AstraZeneca's Calquence Gains EU Approval for Mantle Cell Lymphoma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32964#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32964#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0709.webp","datePublished":"2025-05-07T06:07:02+00:00","dateModified":"2025-05-07T06:07:03+00:00","description":"UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European Union (EU) for its Calquence (acalabrutinib), a second-generation selective Bruton tyrosine kinase (BTK) inhibitor. The drug can now be used in combination with bendamustine and rituximab to treat adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval follows the recent nod for Calquence monotherapy for the treatment of adult patients with relapsed or refractory MCL in the region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32964#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32964"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32964#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0709.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0709.webp","width":1080,"height":608,"caption":"AstraZeneca's Calquence Gains EU Approval for Mantle Cell Lymphoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32964#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0709.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32964"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32964\/revisions"}],"predecessor-version":[{"id":32967,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32964\/revisions\/32967"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32966"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}